Tapentadol

Tapentadol is an opioid analgesic used for severe pain that cannot be managed with other treatments. It is available in immediate-release tablets and extended-release tablets, with distinct approved uses for each formulation.

• Nucynta tablets treat severe acute pain in adults and in children aged 6 and older who weigh at least 40 kg, when alternative treatments are inadequate.
• Tapentadol tablets and Tapentadol Hydrochloride tablets treat severe acute pain in adults when other treatments are not adequate.
• Nucynta ER (extended-release) treats severe, ongoing pain in adults requiring around-the-clock opioid therapy, including severe neuropathic pain associated with diabetic peripheral neuropathy (DPN).
• Tapentadol extended-release tablets treat severe, persistent pain in adults requiring an extended period of daily opioid treatment, including neuropathic pain from diabetic peripheral neuropathy.
• All formulations are reserved for patients for whom alternative options are ineffective, not tolerated, or inadequate.
• Extended-release formulations are not for as-needed (prn) pain relief.

Tapentadol is a centrally acting synthetic analgesic — meaning it works directly on the brain and spinal cord rather than at the site of injury. It works through two mechanisms: it activates mu-opioid receptors (the same receptors targeted by morphine and similar drugs), which reduces the perception of pain; and it inhibits the reuptake of norepinephrine, a chemical messenger that also plays a role in dampening pain signals. In animal studies, both actions contribute to pain relief, though the exact relevance of each in humans is still being studied.

Tapentadol is taken by mouth. Immediate-release tablets can be taken with or without food and are typically used for short-term acute pain. Extended-release tablets are taken approximately twice daily (about every 12 hours) and may also be taken with or without food.

• Extended-release tablets must be swallowed whole — never crushed, chewed, broken, or dissolved.
• Dosing is individualized by your prescriber based on your pain, history, and risk factors — always use the lowest effective dose for the shortest time needed.
• Do not adjust your dose on your own; contact your prescriber if your pain is not controlled.

The most common side effects of tapentadol include:

• Nausea
• Constipation
• Dizziness
• Headache
• Drowsiness (somnolence)
• Vomiting
• Itching or flushing

Serious reactions — including dangerously slowed breathing, severe low blood pressure, seizures, serotonin syndrome, and adrenal insufficiency — can also occur. Seek emergency care immediately if you experience slow or stopped breathing, extreme drowsiness, or signs of a severe reaction.

• Respiratory depression (slowed or stopped breathing) is the most dangerous risk — it can be fatal and is most likely when starting treatment or increasing the dose, especially in elderly, debilitated, or patients with lung conditions.
• Addiction, abuse, and misuse are real risks with tapentadol, a Schedule II controlled substance. Risk is higher in people with a personal or family history of substance use disorder.
• Alcohol is strictly prohibited during extended-release tapentadol use — it can cause a fatal spike in drug levels.
• Combining with CNS depressants (benzodiazepines, sleep aids, antipsychotics, other opioids) can cause coma or death.
• Opioid-induced hyperalgesia (OIH): in some cases, the drug can paradoxically increase pain sensitivity — tell your doctor if your pain worsens despite dose increases.
• Neonatal opioid withdrawal syndrome: extended use during pregnancy can cause life-threatening withdrawal symptoms in newborns.
• Serotonin syndrome: combining tapentadol with serotonergic medications can cause a dangerous, potentially life-threatening reaction.
• Keep naloxone accessible and make sure those around you know how to use it in an emergency.

Tapentadol interacts with several common medications and substances — always tell your prescriber and pharmacist everything you take:

• Benzodiazepines and CNS depressants (sedatives, sleep aids, muscle relaxants, antipsychotics): combined use can cause severe sedation, stopped breathing, coma, or death.
• Alcohol: raises tapentadol blood levels to potentially fatal levels — completely avoid while taking extended-release formulations.
• MAOIs (e.g., phenelzine, linezolid, tranylcypromine): can cause serotonin syndrome or severe opioid toxicity — do not use tapentadol within 14 days of an MAOI.
• Serotonergic drugs (SSRIs, SNRIs, tricyclic antidepressants, triptans, tramadol, mirtazapine): risk of serotonin syndrome.
• Muscle relaxants (e.g., cyclobenzaprine): increased risk of respiratory depression.
• Diuretics: tapentadol may reduce their effectiveness by triggering release of antidiuretic hormone.
• Anticholinergic drugs: increase risk of severe constipation or urinary retention.
• Mixed opioid agonist/antagonists (e.g., buprenorphine, nalbuphine): may block tapentadol's effects or trigger withdrawal — avoid combination.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

• Do not take tapentadol if you have significant respiratory depression, severe unmonitored asthma, a known or suspected bowel blockage, or a hypersensitivity (allergic reaction) to tapentadol.
• Do not take tapentadol if you are currently using or have used an MAOI within the past 14 days.
• Tell your doctor about any history of substance use disorder, addiction, or major depression — risk of misuse is higher.
• If you are pregnant, long-term use can cause neonatal opioid withdrawal syndrome in your newborn — discuss the risks carefully with your doctor.
• If breastfeeding, monitor your infant for unusual sleepiness or breathing problems; tapentadol is likely present in breast milk.
• Older adults (65+) are at higher risk for respiratory depression and should be started at lower doses with careful monitoring.
• Children under age 6 or weighing less than 40 kg: tapentadol tablets are not recommended; extended-release formulations have not been studied in children.
• Moderate to severe liver impairment: tapentadol exposure increases significantly — dose adjustment or avoidance may be required.
• Severe kidney or liver impairment: extended-release tapentadol is not recommended.
• Long-term use may affect hormone levels and fertility in both men and women.

An overdose of tapentadol can cause dangerously slow or stopped breathing, extreme drowsiness, muscle limpness, cold or clammy skin, pinpoint pupils, low blood pressure, and in severe cases, coma or death. If you suspect an overdose, call 911 immediately and administer naloxone if available. Because extended-release tablets continue releasing tapentadol for 24 to 48 hours or longer after ingestion, prolonged monitoring and repeat doses of naloxone may be needed.

Tapentadol acts on the brain and nervous system to relieve pain, but also causes several other body-wide effects. It slows breathing by acting on the brain's respiratory centers and causes constipation by reducing movement in the intestines. It may cause a drop in blood pressure, especially when standing up (orthostatic hypotension), and can cause pinpoint pupils. With long-term use, it may suppress certain hormone levels, potentially affecting libido, fertility, or menstrual cycles, and may have modest effects on the immune system.

After swallowing extended-release tablets, tapentadol reaches peak blood levels in about 3 to 6 hours, with an average half-life (the time it takes the body to clear half the drug) of about 5 hours. About 97% of the drug is broken down (metabolized) in the body — mostly in the liver — and nearly all of it is eliminated through the kidneys. Food has only a minor effect on absorption, so extended-release tablets can be taken with or without food. People with moderate to severe liver impairment have significantly higher drug levels, and the drug accumulates more in people with worsening kidney function.

Store at 20°C-25°C (68°F-77°F); excursions permitted to 15° - 30°C (59° - 86°F) . Protect from moisture. Store tapentadol tablets securely and dispose of properly .